Related Experiment Video
Updated: May 7, 2026

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Anaplastic lymphoma kinase rearrangement-associated renal cell carcinoma: Rare subset case report
Hamad S AlAkrash1, Hisham M Ghabbani1, Faisal A AlSaleh2
1Urology Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Abstract:
Anaplastic lymphoma kinase rearrangement-associated renal cell carcinoma (ALK-RCC) is a rare subtype of renal cell carcinoma characterized by genetic rearrangements involving the ALK gene. Managing ALK-RCC is challenging due to its rarity and limited treatment options. Targeted therapies directed at the ALK gene have shown promise. ALK-RCC is a rare subtype of renal cell carcinoma with unique clinical and pathological features. ALK inhibitors may hold promise as a targeted therapy for ALK-RCC. Further research is needed to understand the behavior of ALK-RCC and develop effective treatment strategies.
Insights
Anaplastic lymphoma kinase rearrangement-associated renal cell carcinoma (ALK-RCC) is a rare kidney cancer. ALK inhibitors show promise as a targeted therapy for this unique subtype.
Area of Science:
- Oncology
- Genetics
- Pathology
Background:
- Anaplastic lymphoma kinase rearrangement-associated renal cell carcinoma (ALK-RCC) is a rare kidney cancer subtype.
- Its rarity presents challenges in management and treatment.
- Genetic rearrangements involving the ALK gene define this specific cancer.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
09:49Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019